Indianapolis-based Eli Lilly has been granted exclusive licensing rights to a new anti-cancer technology.
The deal between the drug-maker and ImmunoGen, Inc., could be worth up to $200 million.
The method uses antibodies to deliver cancer-killing agents to cancer cells. It spares nearby, healthy cells from destruction.
The deal was made possible by a 2011 agreement.